ArticleBioengineering (Basel, Switzerland)2025
AI-Powered Spectral Imaging for Virtual Pathology Staining.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ultraviolet Sensing-Guided Biomedical Systems: From Label-Free Imaging to Dosimetry and Therapy Feedback.Biosensors · 2026Review
- Thyroid cancer detection and classification using spectral imaging and artificial intelligence.Scientific reports · 2026Article
- Liver Cancer: Artificial Intelligence (AI)-Based Integrated Therapeutic Approaches.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pathological analysis of tissue biopsies remains the gold standard for diagnosing cancer and other diseases. However, this is a time-intensive process that demands extensive training and expertise. Despite its importance, it is often subjective and not entirely error-free. Over the past decade, pathology has undergone two major transformations. First, the rise in whole slide imaging has enabled work in front of a computer screen and the integration of image processing tools to enhance diagnostics. Second, the rapid evolution of Artificial Intelligence has revolutionized numerous fields and has had a remarkable impact on humanity. The synergy of these two has paved the way for groundbreaking research aiming for advancements in digital pathology. Despite encouraging research outcomes, AI-based tools have yet to be actively incorporated into therapeutic protocols. This is primary due to the need for high reliability in medical therapy, necessitating a new approach that ensures greater robustness. Another approach for improving pathological diagnosis involves advanced optical methods such as spectral imaging, which reveals information from the tissue that is beyond human vision. We have recently developed a unique rapid spectral imaging system capable of scanning pathological slides, delivering a wealth of critical diagnostic information. Here, we present a novel application of spectral imaging (SI) for virtual Hematoxylin and Eosin (H&E) staining using a custom-built, rapid Fourier-based SI system. Unstained human biopsy samples are scanned, and a Pix2Pix-based neural network generates realistic H&E-equivalent images. Additionally, we applied Principal Component Analysis (PCA) to the spectral information to examine the effect of down sampling the data on the virtual staining process. To assess model performance, we trained and tested models using full spectral data, RGB, and PCA-reduced spectral inputs. The results demonstrate that PCA-reduced data preserved essential image features while enhancing statistical image quality, as indicated by FID and KID scores, and reducing computational complexity. These findings highlight the potential of integrating SI and AI to enable efficient, accurate, and stain-free digital pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.